Overview
- ANVISA authorized Butantan‑DV for people ages 12 to 59 following extensive trials conducted across Brazil.
- In studies of more than 16,000 participants, the vaccine showed 91.6% efficacy against severe dengue and roughly 80% overall protection over two years.
- The single dose is expected to simplify vaccination efforts compared with TAK‑003, which requires two doses three months apart according to the WHO.
- The Butantan Institute developed the shot over about eight years, and its results were published in peer‑reviewed research.
- Wider availability beyond Brazil will hinge on production scale‑up and further regulatory or WHO review.